Evotec Completes First Phase-I Study With EVT 401
EVT 401, a small molecule drug candidate to orally treat inflammatory conditions
Evotec has completed first phase-I study with P2X7 receptor antagonist, EVT 401. EVT 401 is a small molecule drug candidate and a potentially novel approach to orally treat inflammatory conditions, such as Rheumatoid Arthritis.
The study was a double-blind, placebo controlled study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of EVT 401. A total of 96 healthy male volunteers received single oral ascending doses of the compound, as a suspension or capsule. The study demonstrated that the compound was safe and well tolerated and there were no serious adverse events or withdrawals.
In addition, the pharmacodynamic assay used in the study demonstrated the ability of EVT 401 to block ATP-stimulated IL-1ß release in whole blood samples taken from volunteers, thereby proving on target activity at well tolerated oral doses.
Dr. Werner Lanthaler, CEO of Evotec, said: We are encouraged that EVT 401 showed positive results in its first human trial. It was well tolerated and demonstrated the desired pharmacodynamic activity in healthy volunteers. We are now focussing our efforts on optimizing the oral dose formulation, completing the Phase I studies, and preparing Phase II studies in Rheumatoid Arthritis.
Related Insight
Suppliers Directory
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.